2025 France Age-Related Mascular Degeneration Revenue Opportunities Report
Description
The 2025 France Age-Related Mascular Degeneration Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) field in France include Sanofi, Horus Pharma, Fovea Pharmaceuticals, and Laboratoires THEA. Sanofi acquired the French biotech Fovea in 2009 for €370 million and has since heavily invested over $1 billion in ophthalmology, positioning AMD as a key growth area. Horus Pharma, based in Nice and with over 100 employees, is expanding quickly in eye care treatment, including retinal diseases. Laboratoires THEA, with a legacy dating to 1870, employs 1500 people and has developed AMD risk assessment tools, marking it as a major biotech player in the field.
Globally impacting companies with strong presence or products used in France's AMD market also include Roche Holding AG, Novartis, Bayer, and Regeneron Pharmaceuticals, which are associated with AMD treatments like Eylea, Lucentis, and Beovu, the leading therapies by revenue and growth segments in France. Roche and Novartis are key providers of these biologics, with Roche’s Eylea holding the largest market share in 2021 at 53.7%. Bayer and Regeneron also contribute substantially to AMD therapeutics marketed in France.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) field in France include Sanofi, Horus Pharma, Fovea Pharmaceuticals, and Laboratoires THEA. Sanofi acquired the French biotech Fovea in 2009 for €370 million and has since heavily invested over $1 billion in ophthalmology, positioning AMD as a key growth area. Horus Pharma, based in Nice and with over 100 employees, is expanding quickly in eye care treatment, including retinal diseases. Laboratoires THEA, with a legacy dating to 1870, employs 1500 people and has developed AMD risk assessment tools, marking it as a major biotech player in the field.
Globally impacting companies with strong presence or products used in France's AMD market also include Roche Holding AG, Novartis, Bayer, and Regeneron Pharmaceuticals, which are associated with AMD treatments like Eylea, Lucentis, and Beovu, the leading therapies by revenue and growth segments in France. Roche and Novartis are key providers of these biologics, with Roche’s Eylea holding the largest market share in 2021 at 53.7%. Bayer and Regeneron also contribute substantially to AMD therapeutics marketed in France.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
